Novel multi-target marker combination for detecting pancreatic cancer and application of novel multi-target marker combination
By screening out the new methylation site combination and combining the protein marker CA19-9, the problem of insufficient sensitivity and specificity of early screening of pancreatic cancer in the prior art is solved, and efficient pancreatic cancer detection, AUC value and specificity are achieved. The detection process has been significantly improved.
Patent Information
- Application Number
- CN202411152231.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-15
AI Technical Summary
The lack of high-performance markers in the prior art for early screening of pancreatic cancer, resulting in the failure of clear diagnosis in early stages of pancreatic cancer patients, and the sensitivity and specificity of existing markers such as CA 19-9 and CEA are low , it is difficult to effectively distinguish between pancreatic cancer and pancreatitis.
By screening out novel methylation sites from high-deep whole-genome methylation data of pancreatic cancer tissue, percancer tissue, chronic pancreatitis plasma, pancreatic cancer plasma and normal plasma samples, and using them in combination with traditional markers, improve Detection sensitivity and specificity of pancreatic cancer. Specific methods include screening out a combination of 6 methylation sites and testing with protein marker CA19-9.
With fewer marker detection, efficient detection of pancreatic cancer has been achieved, with AUC value reaching 0.986, sensitivity reaching 93%, specificity reaching 97%, and detection process is simpler and more efficient, which can effectively distinguish pancreatic cancer from non- Patients with pancreatic cancer.
Smart Images

Figure CN118957071A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of cancer screening, and in particular to a novel multi-target pancreatic cancer detection marker combination and application thereof. Background Art
[0002] Pancreatic cancer is a highly malignant cancer, known as the "king of cancers". In most countries in the world, including China, the five-year survival rate of pancreatic cancer is below 10%, which is much lower than other highly prevalent malignant tumors such as colorectal cancer, esophageal cancer, and liver cancer. One of the reasons for the extremely low survival rate of pancreatic cancer is that there are no obvious clinical symptoms in the early stage of pancreatic cancer, and there is a lack of high-performance markers for screening and diagnosing early and middle stage pancreatic cancer in the clinic. Commonly used blood markers such as CA 19-9 and CEA in clinical practice have low sensitivity and specificity for screening and diagnosing pancreatic cancer, resulting in most pancreatic cancer patients failing to receive a clear diagnosis in the early stage. Once pancreatic cancer progresses to the middle and late stages, the possibility of patients receiving radical surgical resection is greatly reduced, and other effective non-surgical treatments for pancreatic cancer are very scarce in the clinic (Diagnostics 2019; 9:18). Therefore, the development of high-performance tumor markers for screening pancreatic cancer, especially early pancreatic cancer, is a huge unmet clinical need and an important direction that the scientific and clinical oncology communities are committed to.
[0003] cfDNA (cell free DNA) is a small fragment of DNA other than cellular components in the blood. In theory, cfDNA is released into the blood after cell apoptosis or necrosis. It is usually about 150 to 200 base pairs in length and has a half-life of about 0.5-1 hour (Nature Reviews Genetics 2019; 20:71-88). In normal humans, the cfDNA content is extremely low, while the cfDNA content in cancer patients is significantly increased. In cancer patients, the DNA released by tumors measured in peripheral blood is also called circulating tumor DNA (ctDNA), which is a part of cfDNA. In cancer patients, the proportion of ctDNA to cfDNA varies greatly, ranging from less than 0.01% to more than 90%. For healthy asymptomatic people, if the application of liquid biopsy to early diagnosis of tumors is successful, "blood test for cancer" will become a reality, which is undoubtedly the most attractive feature of liquid biopsy. Application exploration in this area is currently underway (Annals of Oncology, 2020, 31(6):745-759; Science, 2020, 369(6499):eabb9601).
[0004] ctDNA mutation is a possible direction for early screening and diagnosis of tumors. In a 2018 CancerSEEK pan-cancer screening study that combined ctDNA mutation and protein detection, when the detection specificity was set at 99%, the sensitivity of detecting different solid tumors was between 69-98%, with lung cancer being the lowest and colorectal cancer (CRC) being the highest. Among them, the sensitivity of pancreatic cancer was 87% (Science, 2018, 359(6378):926-930). This discovery shows the exciting prospect of early screening and diagnosis of cancer through ctDNA mutation detection. However, due to some limitations of this study, such as the small number of samples of a single cancer, most of the included tumor cases were in the middle and late stages rather than the early stages, and more importantly, the research results were not verified in independent samples, so the effectiveness of its results in the real world needs more exploration.
[0005] Other important markers in the genome include copy number variation (CNV) and methylation, both of which are early events (Hallmarks) in the development of cancer. Researchers have reported the use of cfDNA methylation markers for screening malignant tumors such as liver cancer, colorectal cancer, and breast cancer (Nature materials 2017; 16: 1155-61; Clinical epigenetics 2018; 10: 1-10; Breast Cancer Research 2016; 18: 1-14). An article published in Annals of Oncology in March 2020 used a methylation scheme to analyze the screening performance of >50 types of tumors. When the researchers set the specificity at 99%, the average detection sensitivity of different cancer types was 43.9% in stage I-III tumors and 54.9% in stage I-IV tumors. Among them, for pancreatic cancer, its sensitivity is 63%, 83%, 75%, and 100% in stages I, II, III, and IV, respectively (Annals of Oncology, 2020, 31(6):745-759). Several limitations can be seen from this. For example, the performance for stage III cases is lower than that for stage II, which is most likely due to the randomness caused by the small sample size. Although the performance for stage IV cases is 100%, the screening performance for stage I patients is only 63%. The clinical significance of early screening for pancreatic cancer in early cases is far higher than that in late cases, because only when it is discovered in the early stage can the patient have the opportunity to undergo radical surgical resection. For patients discovered in the late stage, there is no very effective means clinically to significantly improve survival.
[0006] Therefore, it is urgent to find a marker combination that can effectively distinguish early pancreatic cancer from pancreatitis, so as to achieve high-sensitivity and high-specificity pancreatic cancer screening, promote early detection and early treatment of pancreatic cancer, and meet urgent clinical needs. Summary of the invention
[0007] In view of the problems existing in the prior art, the present invention provides a novel multi-target pancreatic cancer detection combination marker and kit and its application in pancreatic cancer detection. By finding a series of novel methylation sites that can effectively distinguish pancreatic cancer and pancreatitis patients from the high-depth whole genome methylation (WGBS) data of pancreatic cancer tissue, paracancerous tissue, chronic pancreatitis plasma, pancreatic cancer plasma, and normal plasma samples, it can be used for efficient detection of pancreatic cancer; combining the novel gene methylation site with other pancreatic cancer detection markers (such as CA 19-9, CEA, etc.) can further improve the AUC value and improve the sensitivity and specificity of pancreatic cancer screening.
[0008] The research team found 9 methylation sites with significantly different methylation levels in patients with pancreatic cancer and chronic pancreatitis, and further accurately screened a combination of 6 methylation sites, achieving efficient detection of pancreatic cancer with fewer markers.
[0009] In one aspect, the present invention provides a use of a marker for preparing a pancreatic cancer detection reagent, wherein the marker is any one or more nucleotide sequences selected from Seq ID NO.1 to Seq ID NO.12 as shown in Table 1 or a combination of their completely complementary sequences.
[0010] Table 1. Pancreatic cancer detection sites
[0011]
[0012] The present invention screened out CpG-based methylation sites that distinguish pancreatic cancer from non-pancreatic cancer by performing methylation sequencing on plasma free DNA from pancreatic cancer patients, chronic pancreatitis patients and normal subjects, and then further verified it with a large number of pancreatic cancer and non-pancreatic cancer plasma samples, and finally discovered and identified 6 target sequences with abnormal methylation in pancreatic cancer patients. Clinical verification has shown that the methylation levels of the 6 new target sequences provided by the present invention are significantly different in pancreatic cancer and chronic pancreatitis patients.
[0013] The six target sequences are double-stranded DNAs with complementary sequences. It is understandable that the methylation site target sequence provided by the present invention can be either the sense strand or the antisense strand.
[0014] In some embodiments, the marker is a combination of 1, 2, 3, 4, 5 or 6 nucleotide sequences selected from Seq ID NO.1 to Seq ID NO.12 in the sequence listing or their completely complementary sequences.
[0015] Furthermore, the marker comprises a nucleotide sequence shown by any one or more of Seq ID NO.1, Seq ID NO.2, Seq ID NO.3, Seq ID NO.9, Seq ID NO11, and Seq ID NO.12.
[0016] Furthermore, the marker is a combination of any two, three or six nucleotide sequences of Seq ID NO.1, Seq ID NO.2, Seq ID NO.3, Seq ID NO.9, Seq ID NO11, Seq ID NO.12 or their completely complementary sequences.
[0017] The AUC values, detection sensitivity, and specificity of the methylation sites corresponding to Seq ID NO.1, Seq ID NO.2, and Seq ID NO.12 were significantly higher than those of the other methylation sites.
[0018] Further, the marker comprises a combination of the nucleotide sequences shown in Seq ID NO.1 and Seq ID NO.2 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.2 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.11 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.2, Seq ID NO.11 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.3, Seq ID NO.9 and Seq ID NO.11 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.3, Seq ID NO.9 and Seq ID NO.11 or their completely complementary sequences. A combination of the nucleotide sequence shown in NO.12 or its completely complementary sequence, or a combination of the nucleotide sequences shown in Seq ID NO.9, Seq ID NO.11 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2, Seq ID NO.3, Seq ID NO.9, Seq ID NO11, Seq ID NO.12 or their completely complementary sequences.
[0019] Furthermore, the marker is a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2 and Seq ID NO.12 or their completely complementary sequences.
[0020] After verification by a large number of clinical pancreatic cancer and pancreatitis samples, the present invention has found three highly methylated sites from the above six target sequences that can particularly sensitively and specifically distinguish pancreatic cancer patients, pancreatitis patients, and benign control individuals, respectively having the sequences shown in the sequence table Seq ID NO.1, Seq ID NO.2, and Seq ID NO.12. Data from the detection of clinical plasma samples of pancreatic cancer and pancreatitis show that the AUC value of pancreatic cancer detection using only these three methylation sites can reach 0.942, the sensitivity reaches 90%, and the specificity reaches 97%; the study has shown that the diagnostic performance of pancreatic cancer of these three methylation sites is not lower than or even slightly higher than the combination of six methylation sites, and the detection process is simpler and more efficient, with the most application prospects.
[0021] Furthermore, the marker also includes a protein marker, and the protein marker is cancer antigen 19-9 (CA19-9).
[0022] Due to technical limitations, the performance of detecting cancer through methylation sites alone also has a certain ceiling. Multi-omics combining multiple categories such as genomics, epigenetics, and proteomics has become a development trend. Several clinical studies have shown that the sensitivity and specificity of multi-omics marker detection are better than those of single-omics markers. Therefore, based on the methylation sites provided by the present invention, combined with protein level detection, the AUC value of pancreatic cancer detection is further improved, and the detection sensitivity and specificity are improved.
[0023] The level of the protein marker CA19-9 provided by the present invention in the serum of pancreatic cancer patients is significantly different from that in the serum of pancreatitis patients.
[0024] Studies have shown that by detecting the methylation levels of the series of novel methylation sites provided by the present invention, combined with the CA19-9 protein level in serum samples, pancreatic cancer patients and non-cancer individuals can be distinguished more sensitively and specifically. Data from clinical pancreatic cancer and pancreatitis samples show that the combination provided by the present invention can effectively distinguish pancreatic cancer from non-cancer patients, with an AUC value of up to 0.986, a sensitivity of 93%, and a specificity of 97%.
[0025] On the other hand, the present invention provides a primer combination for detecting pancreatic cancer, wherein the primer combination is any one or more of the 12 primer and probe combinations shown in Table 2.
[0026] Table 2. Primer and probe combinations
[0027]
[0028] In some embodiments, the primer combination is any 2, 3 or 6 selected from the primer and probe combinations shown in Table 2.
[0029] Furthermore, the primer combination is 3 sets of primer and probe combinations as shown in Table 3.
[0030] Table 3.6 primer and probe combinations
[0031]
[0032] Furthermore, the primer combination also includes a primer and a probe for an internal reference gene, the internal reference gene COL2A1 has a sequence as shown in Seq ID NO.13 in the sequence list, its forward primer has a sequence as shown in Seq ID NO.14 in the sequence list, the reverse primer has a sequence as shown in Seq ID NO.16 in the sequence list, and the probe has a sequence as shown in Seq ID NO.15 in the sequence list.
[0033] In yet another aspect, the present invention provides a kit for detecting pancreatic cancer, the kit comprising any one of the primer and probe combinations described above.
[0034] Furthermore, the kit or chip also includes reagents or materials for detecting protein, and the protein is CA19-9.
[0035] On the other hand, the present invention provides a marker combination for detecting pancreatic cancer, the marker combination comprising a methylation site and a protein marker, the methylation site being any one or more selected from the sequence table Seq ID NO.1 to Seq ID NO.12; the protein marker is CA19-9.
[0036] In some embodiments, the methylation site in the marker combination is a combination of any two, three or six nucleotide sequences of Seq ID NO.1, Seq ID NO.2, Seq ID NO.3, Seq ID NO.9, Seq ID NO11, Seq ID NO.12 or their completely complementary sequences.
[0037] In some embodiments, the marker comprises a combination of the nucleotide sequences shown in Seq ID NO.1 and Seq ID NO.2 or their fully complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.2 and Seq ID NO.12 or their fully complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1 and Seq ID NO.12 or their fully complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2 and Seq ID NO.12 or their fully complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.11 and Seq ID NO.12 or their fully complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.2, Seq ID NO.11 and Seq ID NO.12 or their fully complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.3, Seq ID NO.9 and Seq ID NO.11 or their fully complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.3, Seq ID NO.9 and Seq ID NO.11 or their fully complementary sequences. A combination of the nucleotide sequence shown in NO.12 or its completely complementary sequence, or a combination of the nucleotide sequences shown in Seq ID NO.9, Seq ID NO.11 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2, Seq ID NO.3, Seq ID NO.9, Seq ID NO11, Seq ID NO.12 or their completely complementary sequences.
[0038] In some embodiments, the methylation sites in the marker combination are a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2 and Seq ID NO.12 or their completely complementary sequences.
[0039] In yet another aspect, the present invention provides a marker combination for detecting pancreatic cancer, wherein the marker combination comprises a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2 and Seq ID NO.12 or their completely complementary sequences.
[0040] The method for detecting pancreatic cancer in vitro using the methylation sites provided by the present invention comprises the following steps:
[0041] 1) Separating genomic DNA or plasma free DNA from the biological sample to be tested;
[0042] 2) detecting the methylation status of the methylation site or the combination of methylation sites;
[0043] 3) The state of the biological sample is determined by the state of the target gene methylation site, and in vitro detection of pancreatic cancer is achieved.
[0044] The method for detecting pancreatic cancer in vitro by using the methylation site and protein combination provided by the present invention comprises the following steps:
[0045] 1) Separating genomic DNA or plasma free DNA and serum from the biological sample to be tested;
[0046] 2) detecting the methylation status of the methylation site or the combination of methylation sites and the serum CA19-9 protein level;
[0047] 3) The status of the biological sample is determined by the methylation site status of the target gene and the level of the protein marker, and in vitro detection of pancreatic cancer is achieved.
[0048] In some embodiments, the method further comprises the following steps:
[0049] 1) Separating serum and plasma of the biological sample to be tested, and extracting plasma free DNA of the biological sample to be tested;
[0050] 2) treating the DNA sample obtained in step 1) with a reagent to convert the unmethylated cytosine base at position 5 into uracil, wherein the base converted into uracil has a hybridization ability different from that of the unmethylated cytosine at position 5 and can be detected;
[0051] 3) combining the DNA sample treated in step 2) with a polymerase chain reaction system, wherein the polymerase chain reaction system comprises one or more of the following components: a DNA polymerase, a primer or primer combination of the target sequence, a corresponding probe or probe combination, and a polymerase chain reaction buffer, and generating an amplification product after the polymerase chain reaction occurs;
[0052] 4) Detecting the amplified product with a fluorescently labeled probe or a combination of several probes. If the probe binds to the amplified product, a fluorescent signal can be generated; if the probe cannot bind to the amplified product, no fluorescent signal can be generated;
[0053] 5) determining the methylation status of at least one CpG of the target sequence of the target gene based on whether a fluorescent signal is generated;
[0054] 6) Using magnetic microparticle chemiluminescent immunoassay sandwich method to measure the concentration of CA19-9 in human serum;
[0055] In some embodiments, in the polymerase chain reaction system, the DNA polymerase includes a thermostable DNA polymerase, a hot-start DNA polymerase, or a polymerase lacking 5'-3' exonuclease activity.
[0056] The methylation state of at least one CpG in the target gene target sequence is determined by the cycle threshold Ct value of the PCR reaction or the difference between the Ct values of the target gene. By analyzing the methylation state of DNA in a biological sample using a PCR reaction, the methylation state of one or more target gene target sequences can be easily detected.
[0057] In some embodiments, the unmethylated cytosine at position 5 of DNA is converted into uracil, preferably using a reagent such as bisulfite.
[0058] Methylation modification of position 5 of cytosine is a type of DNA modification widely found in eukaryotic cells. Methylation modification on DNA not only plays an important role in the growth and development of organisms, but also plays a very important role in the process of cell proto-oncogenesis. Since 5-methylcytosine has the same base complementary pairing properties as cytosine, it cannot be directly measured by first-generation sequencing or high-throughput sequencing. Currently, the most commonly used method for detecting 5-methylcytosine is to convert the DNA to be tested by bisulfite. After alkaline hydrolysis, unmethylated cytosine is converted to uracil, while 5-methylcytosine does not undergo conversion. Uracil will complementarily pair with adenine during base complementary pairing, which is different from the complementary pairing of cytosine and guanine. Therefore, by detecting DNA treated with bisulfite, sequencing technology, polymerase chain reaction technology or DNA molecular hybridization-related technology can be used to determine the remaining unconverted cytosines, thereby determining which cytosines in the original DNA molecule have been methylated. Therefore, the present invention preferably uses bisulfite as a methylation conversion reagent, and after processing the DNA sample to be tested, the methylation status of the CpG dinucleotide sequence in the target gene target sequence is determined by sequencing, polymerase chain reaction or DNA molecular hybridization and other related technologies.
[0059] In some embodiments, the method of the present invention is suitable for analyzing samples in a mixed state, such as low-concentration tumor cells present in blood, feces or tissues. Therefore, when analyzing the methylation state of CpG dinucleotide sequences in such samples, those skilled in the art can use quantitative determination methods to determine the methylation level of CpG dinucleotide sequences, such as percentage, ratio, score or degree, etc., rather than the methylation modification state of single nucleotide molecules. Accordingly, the methylation state described in the present invention should be considered to include the methylation modification state of single nucleotide molecules, including the methylation state reflected by the quantitative methylation level.
[0060] In some embodiments, the present invention uses real-time fluorescence quantitative PCR to determine the methylation state, such as real-time fluorescence quantitative PCR using Taqman probes, real-time fluorescence quantitative PCR using fluorescent dyes, methylation-specific PCR (MSP), etc., to determine the methylation state of at least one CpG dinucleotide of the target gene target sequence. Since the base complementary pairing ability of the target sequences of genes with different methylation states is different, the quantitative test of the methylation state in the genomic DNA sample can be performed by real-time fluorescence quantitative PCR, wherein the sequence differentiation occurs at the probe hybridization level.
[0061] As a control, the COL2A1 gene was used in the present invention, and the primers and probes were designed not to cover any CpG dinucleotide positions, and the genomic DNA treated with the reagent was input for detection.
[0062] Real-time fluorescence quantitative PCR can be used with any suitable probe, such as Taqman probe, MGB probe, scorpion probe, etc. The fluorescent probe generally comprises a luminescent group, a nucleic acid sequence, a quenching group, and some chemical modifications or special nucleotides, such as thionucleotides, locked nucleic acids, etc., when necessary.
[0063] In general, during real-time fluorescence quantitative PCR detection, the probe is designed to have a melting temperature that is 10°C higher than that of the forward and reverse primers, so that the probe will be completely bound to the PCR product during annealing and extension. Typically, for example, Taqman probes will be hydrolyzed during the extension process under the action of DNA polymerase with 5'-3' exonuclease activity, causing the fluorescent group and quenching group in the probe to move away, thereby destroying the resonant energy transfer between the fluorescent group and the quenching group, so that the fluorescence emitted by the fluorescent group can be detected by the instrument. At the same time, as the number of PCR products gradually increases, the fluorescence signal will rise exponentially within a certain period of time, and finally present an "S"-shaped amplification curve on the fluorescence quantitative PCR instrument.
[0064] The reaction reagents used for real-time fluorescence quantitative PCR include, but are not limited to: forward and reverse primers of the target gene target sequence, Taqman fluorescent probe, optimized PCR buffer, deoxynucleotide triphosphates, and DNA polymerase with 5'-3' exonuclease activity.
[0065] The present invention detects the target protein level by using, but not limited to, the magnetic microparticle chemiluminescence immunoassay sandwich method, and other commonly used detection methods such as flow cytometry, enzyme-linked immunosorbent assay, etc.
[0066] In some methods, whether the detected biological sample is positive is determined by combining the methylation of the above-mentioned site or site combination and the status of the protein marker level.
[0067] In another aspect, the present invention provides a marker for distinguishing pancreatic cancer from benign pancreatitis, wherein the marker combination comprises a methylation site, and the methylation site is selected from any one or more of Seq ID NO.1 to Seq ID NO.12 in the sequence table.
[0068] In some embodiments, the methylation sites in the marker combination are a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2 and Seq ID NO.12 or their completely complementary sequences.
[0069] Furthermore, protein markers are also included.
[0070] Furthermore, the protein marker is CA19-9.
[0071] The methylation sites for screening pancreatic cancer provided by the present invention have the following beneficial effects:
[0072] 1. It provides 12 new differentially methylated sites, whose methylation status in plasma free DNA of pancreatic cancer patients is significantly different from that in plasma free DNA of pancreatitis patients;
[0073] 2. Any combination of 2, 3 or 6 methylation sites among the 12 methylation sites can be used to detect pancreatic cancer with high sensitivity and specificity;
[0074] 3. Among the 12 methylation sites, the three methylation sites consisting of Seq ID NO.1, Seq ID NO.2, and Seq ID NO.12 have a higher AUC value for pancreatic cancer detection, with better sensitivity and specificity;
[0075] 4. We found three methylation sites (Seq ID NO.1, Seq ID NO.2, and Seq ID NO.12) combined with the protein marker CA19-9 for non-invasive, rapid in vitro detection of pancreatic cancer, which can more effectively distinguish pancreatic cancer patients from other pancreatic diseases, with an AUC value of up to 0.986, a sensitivity of 93%, and a specificity of 97%;
[0076] 5. Convenient, fast, and the test results are highly consistent with the clinical gold standard test results. BRIEF DESCRIPTION OF THE DRAWINGS
[0077] Figure 1 The heat map of WGBS sequencing data of pancreatic cancer and healthy human tissue samples in Example 1, wherein tumor is a pancreatic cancer tissue sample; normal is a healthy human tissue sample;
[0078] Figure 2It is a box plot comparing the methylation levels of the 12 methylation sites in Example 1 in different types of samples;
[0079] Figure 3 This is a schematic diagram of the results of the fluorescence quantitative PCR reaction of pancreatic cancer patient samples in Example 2;
[0080] Figure 4 This is a schematic diagram of the detection results of the fluorescent quantitative PCR reaction of healthy human samples in Example 2;
[0081] Figure 5 The ROC curve obtained by the normalized results of the three methylation site detection in Example 3;
[0082] Figure 6 This is the ROC curve obtained by combining the normalized results of the three methylation sites in Example 3 with the CA19-9 protein detection. DETAILED DESCRIPTION
[0083] The present invention is further described in detail below in conjunction with the accompanying drawings and examples. It should be noted that the following examples are intended to facilitate understanding of the present invention and do not have any limiting effect on it. The reagents used in this example are all known products and were obtained by purchasing commercially available products.
[0084] Example 1 Screening of gene methylation sites
[0085] Based on the actual clinical application of the product, this example discovered and identified 36 CpG sites as candidate qPCR targets, and screened out 12 target sequences that were abnormally methylated in pancreatic cancer patients. The specific screening process for pancreatic cancer methylation qPCR candidate targets is as follows:
[0086] The screening process consisted of two stages. In the first stage, WGBS data of 10 pairs of pancreatic cancer tissues and adjacent adjacent tissues and WGBS data of 20 normal human cfDNA samples were collected. Figure 1 ) to screen the regions showing high methylation in pancreatic cancer tissue and demethylation in adjacent cancer tissue (i.e., pancreatic cancer panel regions), and design and synthesize corresponding capture probes; the second stage: use the probes to capture and sequence 254 cfDNA samples (including 116 pancreatic cancer cfDNA samples, 94 pancreatitis cfDNA samples, and 44 normal human cfDNA samples), and by analyzing these data, screen out 36 CpG sites from the pancreatic cancer panel region that can best distinguish pancreatic cancer cfDNA samples from non-pancreatic cancer cfDNA samples, with good complementarity and continuity as candidate qPCR targets.
[0087] According to the regional settings, the sequences were downloaded from the NCBI database website, and the sequences were converted into methylation-converted sequences using the Methyl Primer Express v1.0 software, that is, the "C" in the "CG" sequence was retained, and all other "C"s were converted to "T". As shown below. In order to ensure that the sequence in the designed region has a relatively balanced GC content distribution, the antisense strand was also considered as a template design when selecting the sequence. According to the universal primer design principles, corresponding detection primers and probes were designed for the 36 highly methylated regions. The designed primers were screened and verified using the following concentrations of templates:
[0088] 1) Select the pure positive template MJ, which is purified after SSSI enzyme treatment. All CG sites are methylated and it is the best positive substance template for methylation test verification. 100pg / μl and 10pg / μl are selected to represent the medium and low concentration levels.
[0089] 2) Select pure negative template WBC, which is taken from the peripheral blood leukocyte gDNA of healthy people, contains a complete set of gDNA background, and after ultrasonic interruption, it better simulates the state of human cfDNA. Select 1ng / μl as a simulation of the real high concentration sample.
[0090] 3) Low-abundance mixed template MJ / WBC, which is used to simulate the mixed state in real samples, and usually 5% is used as the state of simulating low-abundance samples.
[0091] According to the design combination of primer screening, each combination was prepared with a methylation detection system for comparison, and 100pg / μl and 10pg / μl methylation positive templates, 1ng / μl methylation negative templates and 5% abundance methylation mixed templates were used for comprehensive screening. The screening criteria are shown in Table 4. Finally, the primer combination was selected based on the specificity, detection rate and amplification effect Ct value as the judgment index, and the screening results are shown in Table 5.
[0092] Table 4. Sequence combination screening criteria
[0093]
[0094] Table 5. Screening results
[0095]
[0096] (UD means not detected)
[0097] After screening, region 5 had nonspecific amplification problems, so this region was excluded. Regions 6 and 8 had insufficient amplification sensitivity problems, so the above two regions were also excluded. The remaining 9 regions all achieved a relatively good level in detection performance. Subsequently, the clinical performance of the target was verified on clinical samples, including 120 pancreatic cancer samples and 120 chronic pancreatitis samples. A single-region ROC analysis was performed on the test results, and regions with a single-region AUC < 0.75 were excluded to exclude regions with poor clinical performance and reduce the number of regions to meet qPCR detection while ensuring that subsequent regional combination verifications maintain better clinical performance.
[0098] Table 6. Detection performance of the 12 screened regions
[0099]
[0100] After the above screening, 6 target sequences with high methylation in pancreatic cancer patients were finally found and determined (having nucleotide sequences shown as Seq ID NO.1, Seq ID NO.2, Seq ID NO.3, Seq ID NO.9, Seq ID NO11, and Seq ID NO.12, see Table 1 in the manual for details). The box plot of the methylation levels of these 6 abnormal methylation sites in three different types of samples, namely, pancreatitis plasma, pancreatic cancer plasma, and healthy human plasma, is shown in Figure 2 As shown, it can be seen that the methylation levels of the 6 methylation sites screened by the present invention are significantly different for different types of samples, and can effectively distinguish pancreatic cancer from other pancreatic disease patients and normal people.
[0101] Example 2 Detection of pancreatic cancer using two methylation sites (or binding protein markers)
[0102] In this example, two of the six methylation sites selected in Example 1 are selected for the detection of pancreatic cancer. Two methods are used for detection: one is to detect pancreatic cancer using two methylation sites; the other is to detect pancreatic cancer using a combination of two methylation sites and protein markers.
[0103] 1. Using two methylation sites to detect pancreatic cancer
[0104] The specific method of using two methylation sites to detect pancreatic cancer includes the following steps:
[0105] In the first step, serum and plasma of the blood samples were separated, and the plasma free DNA of the biological samples to be tested was extracted using magnetic bead extraction reagents, 30 of which were pancreatic cancer patients and 30 were healthy subjects.
[0106] In step 2, a methylation conversion reagent with bisulfite as the main component is used to perform methylation conversion on the plasma free DNA sample extracted in step 1. 5 ng of plasma free DNA is added to convert unmethylated cytosine into uracil.
[0107] In step 3, the converted plasma free DNA is put into a real-time fluorescence quantitative PCR reaction system containing the target sequence of the detection gene. The fluorescent probes used to detect the two target sequences are labeled with FAM and ROX fluorescent dyes, respectively, and the fluorescent probe used to detect the internal reference gene COL2A1 is labeled with VIC fluorescent dye. The upstream primer, downstream primer and probe refer to the upstream primer, downstream primer and probe corresponding to the two target sequences, respectively, as shown in Table 2.
[0108] The system for fluorescence quantitative PCR detection is a mixture of primers and probes of multiple target genes and internal reference COL2A1 to form a multiplex PCR system, and multiple target genes are detected simultaneously with the internal reference COL2A1. A maximum of 4 target genes and internal references can be detected simultaneously in a single tube. When the number of target genes is greater, multiple tubes are used for detection. In the reaction system, the forward and reverse primers of the target gene sequence are input at a concentration of 0.167 μM, the probe input concentration is 0.167 μM, the real-time fluorescence quantitative PCR reaction system is 30 μL, and the forward and reverse primers of the internal reference gene sequence are input at a concentration of 0.083 μM.
[0109] Step 4: Set up the fluorescence quantitative PCR reaction detection program as shown in Table 7:
[0110] Table 7. Multiplex PCR reaction program
[0111]
[0112] Step 5: Obtain the fluorescence quantitative PCR reaction detection results.
[0113] In this embodiment, the following groups of combinations containing three methylation sites are selected for detection:
[0114] 1. Seq ID NO.1, Seq ID NO.2
[0115] 2. Seq ID NO.2, Seq ID NO.12
[0116] 3. Seq ID NO.1, Seq ID NO.12
[0117] When the two methylation sites corresponding to the nucleotide sequences shown in Seq ID NO.1 and Seq ID NO.2 of the first group are selected, the detection results are as follows Figure 3 , 4 As shown, Figure 3This is the result of the sample from a pancreatic cancer patient. The fluorescent signals of all the methylation sites to be tested were detected, which is positive. Figure 4 For samples from healthy people, only the fluorescence signal of the control gene COL2A1 was detected, and the fluorescence signals of the other sites to be tested were not detected, which was negative.
[0118] The result analysis and judgment method of pancreatic cancer detection using two methylation sites: 1) record the Ct value of each methylation site automatically output by the software; 2) calculate the Ct value of each site in the sample and the internal reference COL2A1 respectively, and then normalize the Ct: ΔCt(target sequence) = |Ct(COL2A1)-Ct(target sequence)|; 3) M methylation sites, the score of the i-th methylation site is Mi. The value of Mi is 0 or 1, and Mi is judged according to the ΔCt(target sequence) value and the corresponding Youden's index. If ΔCt(target sequence)>Youden's index, set Mi=1, if ΔCt(target sequence)<Youden's index, set Mi=0. M-score of methylation=sum_i^m(Mi). The detection results are shown in Table 5.
[0119] The results obtained by using the kit were corrected and analyzed according to logistic regression analysis. The threshold setting of M-score was set according to the ROC curve. And by combining the detection results of the two target methylation sites, the 60 samples were cross-validated by 10 times, and the average was taken to obtain the classification ROC curve, and the AUC value, detection sensitivity and specificity were calculated.
[0120] The detection results of methylation of two target sequences Seq ID NO.1 and Seq ID NO.2 are shown in Table 8. A 10-fold cross validation was performed on these 60 samples, and the average value was taken to obtain the classification ROC curve.
[0121] Table 8. Results of methylation level detection at 2 methylation sites
[0122]
[0123]
[0124]
[0125] According to the sample detection results of this time, the pancreatic cancer detection level of the combination of the two methylation sites of Seq ID NO.1 and Seq ID NO.2 has an AUC of 0.909, a sensitivity of 87%, and a specificity of 95%, which is significantly better than the other two groups of methylation site combinations. The detection and analysis results of groups 2 and 3 are detailed in the subsequent Example 5 and Table 11.
[0126] 2. Detection of pancreatic cancer using a combination of two methylation sites and protein markers
[0127] This embodiment also uses two methylation sites from groups 1 to 6 respectively, combined with a protein marker method to detect pancreatic cancer, wherein the protein marker is CA19-9.
[0128] The detection method of the two methylation sites refers to the above steps 1 to 5. The detection of the protein marker CA19-9 requires the addition of step 6: taking the serum sample separated in step 1, and using the magnetic particle chemiluminescence immunoassay sandwich method to determine the concentration of the protein marker in human serum.
[0129] Magnetic particle chemiluminescent immunoassay sandwich method process: R1 (using the corresponding antibodies of CA19-9 respectively), the sample to be tested, and M magnetic particles are mixed and incubated. Different sites of the protein marker in the sample bind to the antibodies coupled to the magnetic beads to form a solid-phase antibody-antigen complex; after washing, R2 reagent (using the corresponding secondary antibodies of CA19-9 respectively) is added and mixed and incubated, and the above complex binds to the labeled tumor marker antibody to form a solid-phase antibody-antigen-antibody sandwich complex; by washing, the unbound antibodies and other substances are removed. Chemiluminescent substrate 1 and chemiluminescent substrate 2 are added to the reaction complex, and the chemiluminescent reaction is determined by relative luminescence intensity. The luminescence intensity generated is proportional to the concentration of tumor markers in the sample. The protein markers in the sample are tested by magnetic particle chemiluminescent immunoassay sandwich method and the score is determined as the P value. The test results are shown in Table 9.
[0130] Analysis and judgment method: In combination with the above-mentioned analysis and judgment method of the results of using three methylation sites alone to detect pancreatic cancer, it is also necessary to:
[0131] 1) Normalize the CA19-9 test value of each sample separately: P = log10P CA19-9 ; Protein P-score = sum a*P, where a = 3.8618;
[0132] 2) The results obtained by using the kit are corrected and analyzed according to logistic regression analysis. The thresholds of M-score and P-score are set according to the ROC curve.
[0133] The detection performance is improved by integrating two complementary dimensions of methylation and protein markers. The integrated model is PC-score=M-score+P-score. In some embodiments, when the PC-score value is equal to or greater than the set threshold, the result indicates a positive detection of pancreatic cancer and / or early pancreatic cancer in the patient. In some embodiments, when the GC-score value is less than the threshold, the result indicates a negative detection of pancreatic cancer and / or early pancreatic cancer in the patient.
[0134] 3) By integrating the two target methylation sites and the normalized results of the protein CA19-9 test results, these 60 samples were cross-validated by 10 times, and the average value was taken to obtain the classification ROC curve.
[0135] When the two methylation sites corresponding to the nucleotide sequences shown in Seq ID NO.1 and Seq ID NO.2 of the first group were selected, the normalized results after protein CA19-9 detection were combined, and 10 cross validations were performed on these 60 samples, and the average value was taken to obtain the classification ROC curve as shown in the figure below: Figure 5 As shown, the protein CA19-9 detection results are shown in Table 9.
[0136] Table 9. Protein level detection results of different samples
[0137]
[0138]
[0139] When the two methylation sites in the first group are used and the results are normalized after combining with the protein CA19-9 detection, the detection effect of pancreatic cancer can be further improved, with an AUC of 0.949, a sensitivity of 90%, and a specificity of 95%.
[0140] The normalized results of the two methylation sites in groups 2 and 3 after detection of the binding protein CA19-9 are detailed in the subsequent Example 5.
[0141] Example 3 Detection of pancreatic cancer using three methylation sites (or binding protein markers)
[0142] This example selects 3 methylation sites from the 6 methylation sites screened in Example 1 for the detection of pancreatic cancer. Two methods are used for detection: 1. Detection of pancreatic cancer using 3 methylation sites; 2. Detection of pancreatic cancer using a combination of 3 methylation sites and protein markers.
[0143] 1. Using three methylation sites to detect pancreatic cancer
[0144] In this embodiment, the following groups of combinations containing three methylation sites are selected for detection:
[0145] 4. Seq ID NO.1, Seq ID NO.11, Seq ID NO.12
[0146] 5. Seq ID NO.1, Seq ID NO.2, Seq ID NO.12
[0147] 6. Seq ID NO.2, Seq ID NO.11, Seq ID NO.12
[0148] 7. Seq ID NO.3, Seq ID NO.9, Seq ID NO.11
[0149] 8. Seq ID NO.3, Seq ID NO.9, Seq ID NO.12
[0150] 9. Seq ID NO.9, Seq ID NO.11, Seq ID NO.12
[0151] The specific method of using three methylation sites to detect pancreatic cancer includes the following steps:
[0152] In the first step, 60 healthy subjects and pancreatic cancer patients were obtained, including 30 healthy subjects and 30 pancreatic cancer samples. Serum and free plasma DNA of the samples were separated and extracted.
[0153] In the second step, a methylation conversion reagent with bisulfite as the main ingredient is used to perform methylation conversion on the plasma free DNA sample. The plasma free DNA is added to convert the unmethylated cytosine into uracil.
[0154] The third step is to perform real-time fluorescence quantitative PCR detection according to the method of Example 2 using the upstream primers, downstream primers and probes corresponding to the three target sequences as shown in Table 2.
[0155] According to the sample test results, the effect of using the 3 methylation sites in group 5 is significantly better than the pancreatic cancer detection level of other groups. According to the ROC curve, its AUC = 0.942, sensitivity is 90%, and specificity is 97% ( Figure 5 ).
[0156] The detection and analysis results of the three methylation sites in Groups 4 and 6-9 are detailed in the subsequent Example 5.
[0157] 2. Detection of pancreatic cancer using a combination of three methylation sites and protein markers
[0158] In addition to the above test using three methylation sites to detect pancreatic cancer, it is also necessary to add:
[0159] In the fourth step, the serum sample separated in the first step is taken, and the level of CA19-9 protein marker in human serum is measured by magnetic particle chemiluminescence immunoassay sandwich method, and the results are analyzed.
[0160] In the fifth step, the methylation and protein values of each gene in the detected results were normalized. By combining the ΔCt (target gene) results of the three methylation sites and the detection results of the protein marker levels, the 60 samples were cross-validated by 10 times, and the average value was taken to obtain the classification ROC curve ( Figure 6 ).
[0161] The normalized results of the three methylation sites in groups 4 and 6-9 after protein detection are detailed in the subsequent Example 5.
[0162] When the three methylation sites in group 5 are used and combined with the normalized results after CA19-9 protein detection, the detection effect of pancreatic cancer can be further improved, with an AUC of 0.986, a sensitivity of 93%, and a specificity of 97% ( Figure 6 ).
[0163] Example 4 Detection of pancreatic cancer using six methylation sites (or binding protein markers)
[0164] In this embodiment, the six methylation sites selected from Example 1 are used for the detection of pancreatic cancer. Two methods are used for detection: one is to detect pancreatic cancer using the six methylation sites; the other is to detect pancreatic cancer using a combination of the six methylation sites and protein markers.
[0165] 1. Using 6 methylation sites to detect pancreatic cancer
[0166] The specific method of using 6 methylation sites to detect pancreatic cancer includes the following steps:
[0167] In the first step, 60 healthy subjects and pancreatic cancer patients were obtained, including 30 healthy subjects and 30 pancreatic cancer samples. Serum and free plasma DNA of the samples were separated and extracted.
[0168] In the second step, a methylation conversion reagent with bisulfite as the main ingredient is used to perform methylation conversion on the plasma free DNA sample. The plasma free DNA is added to convert the unmethylated cytosine into uracil.
[0169] The third step is to perform real-time fluorescence quantitative PCR detection according to the method of Example 2 using the upstream primers, downstream primers and probes of the six target sequences shown in Table 2.
[0170] The AUC for detection using 6 methylation sites reached 0.940, see Example 5 for details.
[0171] 2. Detection of pancreatic cancer using a combination of 6 methylation sites and protein markers
[0172] The specific method of using the combination of 6 methylation sites and protein markers to detect pancreatic cancer includes the following steps: Based on the above detection of pancreatic cancer using 6 methylation sites, it is also necessary to add:
[0173] In the fourth step, the serum sample separated in the first step is taken, and the level of CA19-9 protein marker in human serum is measured by magnetic particle chemiluminescence immunoassay sandwich method, and the results are analyzed.
[0174] In the fifth step, the methylation and protein values of each gene in the detected results were normalized. By combining the ΔCt (target gene) results of the 6 target genes and the detection results of the protein markers, the 60 samples were cross-validated by 10 times, and the average value was taken to obtain the classification ROC curve, whose AUC-methylation+protein=0.983, sensitivity reached 93%, and specificity reached 96%, see Example 5 for details.
[0175] Example 5 Comparative analysis of performance using different methylation site combinations
[0176] Mathematical modeling analysis of different site combinations was performed on the relative cycle number ΔCT values of the 6 methylation sites (Seq ID NO.1, Seq ID NO.2, Seq ID NO.3, Seq ID NO.9, Seq ID NO11, Seq ID NO.12) of 60 pancreatic cancer and healthy human samples obtained in Example 1 to explore the application of the 6 methylation sites and proteins as a combination of biomarkers for the detection of pancreatic cancer.
[0177] First, we evaluated the performance of the models of single sites among the above six methylation sites for diagnosing pancreatic cancer and calculated their AUC values respectively. The results are shown in Table 10.
[0178] Table 10. Comparison of performance of single methylation sites in diagnosing pancreatic cancer
[0179]
[0180] As can be seen from Table 10, the 6 methylation sites provided in Example 1 have high AUC values for diagnosing pancreatic cancer and have good diagnostic performance, especially the methylation sites corresponding to the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2 and Seq ID NO.12.
[0181] Secondly, the diagnostic efficacy of different combinations of methylation sites or combinations of protein markers listed in Examples 2 to 4 was compared, and the results are shown in Table 11.
[0182] Table 11. Comparison of models with different combinations of methylation sites for the diagnosis of pancreatic cancer
[0183]
[0184] It can be seen from Tables 10 and 11 that the diagnostic performance of using a single methylation site as a diagnostic model is lower than that of the combined model of multiple methylation sites. The diagnostic performance of using a combination of two methylation sites as a diagnostic model is lower than that of the combined model of three methylation sites. The diagnostic performance of the multi-omics model of methylation-binding protein markers is significantly better than that of a single omic marker.
[0185] When a combination of two methylation sites was selected as the diagnostic model, the AUC-methylation and AUC-methylation+protein of Group 1 were the highest. It can be seen that when Group 1 used the two methylation sites corresponding to the nucleotide sequences shown in Seq ID NO.1 and Seq ID NO.2, the diagnostic performance was significantly higher than that of the other two methylation site combinations.
[0186] When a combination of three methylation sites was selected as the diagnostic model, the performance of the three methylation site combinations of groups 4-6 ranked the highest, among which the AUC-methylation and AUC-methylation+protein of group 5 were the highest. It can be seen that when group 5 used the three methylation sites corresponding to the nucleotide sequences shown by SeqID NO.1, Seq ID NO.2, and Seq ID NO.12, the diagnostic performance was significantly higher than that of the other three methylation site combinations.
[0187] When a combination of six methylation sites is selected as the diagnostic model, its diagnostic performance is very close to that of the combination of three methylation sites in Group 5, so the combination of three methylation sites in Group 5 is most preferably used.
[0188] This example further analyzes the diagnostic performance of different methylation site combinations selected from the above, and the results are shown in Table 12.
[0189] Table 12. Comparison of the preferred models of multiple methylation sites for the diagnosis of pancreatic cancer
[0190]
[0191]
[0192] As can be seen from Table 12, the several preferred combinations of methylation sites + proteins in this embodiment can be used for the efficient detection of pancreatic cancer, with the highest AUC reaching 0.986, the sensitivity reaching 93%, and the specificity reaching 97%, truly realizing non-invasive, global, pancreatic cancer screening with higher sensitivity and specificity, which fully meets clinical needs.
[0193] Example 6 Detection of pancreatic cancer using different combinations of three methylation sites (or combined protein markers) in the independent validation set
[0194] The performance of different combinations of three methylation sites and joint proteins was verified in an independent validation set, which included 100 pancreatic cancer samples and 100 chronic pancreatitis samples, and 100 pancreatic cancer samples and 150 healthy human samples.
[0195] (I) 100 pancreatic cancer samples and 100 chronic pancreatitis samples
[0196] The verification results are shown in Table 13 below:
[0197] Table 13. Comparison of the performance of different combinations of methylation sites in pancreatic cancer samples and chronic pancreatitis samples for the diagnosis of pancreatic cancer
[0198]
[0199]
[0200] (II) 100 pancreatic cancer samples and 150 healthy human samples
[0201] The verification results are shown in Table 14 below:
[0202] Table 14. Comparison of the performance of different combinations of methylation sites in pancreatic cancer samples and healthy human samples in the diagnosis of pancreatic cancer
[0203]
[0204] According to Tables 13 and 14, the detection performance can be effectively improved by combining methylation with CA19-9. Groups 1-3 of methylation markers can well distinguish between patients with pancreatic cancer and pancreatitis, as well as pancreatic cancer and healthy people. Among them, the combination 1+2+12 has the best performance.
[0205] Although the present invention is disclosed as above, the present invention is not limited thereto. Any person skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the scope defined by the claims.
[0206] Sequence Listing
[0207] Seq ID NO.1
[0208] Methylation site 1:
[0209] TAATTTATTTTTTTTGGATATTGGAGTTATTAATTGGCGTGTTTTTGTTTATTGGAGTATT
[0210] CGTATATTATTTTAAATTAAAATTATTAAGAGTTTTTTTCGCGTAGATTGTTGTTTTTTTA
[0211] GTTGTTTTCGATTTTGTTTTACGTTTGTCGGTTAGAGTTTTTCGGCGTTTTTTTCGTTTT
[0212] AGCGGAGTGCGTTGGGGCGCGTTAGGGTTAGGTTCGTCGGAGGAGCGCGTTTTTAGT
[0213] TTTTCGCGTATAGAGTCGTATTTCGSeq ID NO.2
[0214] Methylation site 2:
[0215] GTCGGTTGCGGTGGGGTCGGGTTGGAGGTCGCGGGTGAGGTTTGTGGTTAATTTCGC
[0216] GTTGTCGAGGTTTTATTTTTTCGAGTTTAGTTTGATTTTAGGTCGTTTTTAGGTCGGTG
[0217] TTTAGTTGAGGCGGGAACGTTGTAGTTTGGTTGAGCGTGATTTTTAGGTTTTGTGAGG
[0218] AAAAGTCGAGCGCGTTATATCGAGGCGTTAGTCGTTTATTTTATTATAAGGTAAAAGAT
[0219] TTATGTTGTTTTAGTTATTTTAAAGTTGGGAGATATATTGTATTTTTTATTAGATTTCGAA
[0220] TGTTTTTAGTGTSeq ID NO.3
[0221] Methylation site 3:
[0222] AGAGTGGGGGCGTAGGGGGCGGGTTAGGTTTTTGGGCGCGGCGCGGGTTCGGGGGA
[0223] TTCGCGCGGTTGACGTTAGGTTATTTTTTAAATAGAGTCGGTAGCGCGTTTCGTTCGGT
[0224] ATTTTTCGAAGAGTTAGATCGCGGTCGGCGTTAGCGTTATCGTTCGGTTTATTCGTTAG
[0225] TTCGTATAGTCGCGTCGTCGTCGAGCGTTTCGTGAGCGGCGTTTCGAGGATTAGGAAT
[0226] GGGGTTTCGGGCGTTGGGCGCGTTTCGAATTCGGCGTACGTAAGAGTTTGGGAGCGT
[0227] TCGAGTCGTTCGGTTGTTCGGAGTTTTATCGTTTAGGATCGGGAGATGTTGGAAATGT
[0228] AATCGTTTGTTTTTCGAGGASeq ID NO.4
[0229] Methylation site 4:
[0230] TCGAGTGTTGAAAAGGAGGGGCGTTTTTTTGGACGTAGGGGATATTTTTCGAGGGTTT
[0231] TTGTAGGTTTTTTGTAAGGATTAGGCGGTTTAGTTATTTTTCGTTTTGTATTCGTTTTCG
[0232] GTCGCGGCGTGTATTGAAGTTCGTTAGTGTTCGTTTTTGTAGCGAAGGTTTTTATAGTT
[0233] TAGGTTTTATAATTCGGGTAAAGGGGGAGTATTTGTGTGGGTATGGTTTTATAGTTTCG
[0234] TTTAGTATTAGTTTTAAATTTTTGTGSeq ID NO.5
[0235] Methylation site 5:
[0236] ATAGTGGCGCGGTTGGGGCGGGCGGAGGAAGTGGGGGAGTTAAGGAGATATTTTAGC
[0237] GTTGGGATTCGGTAAGTTTTTTTTTTGAGTGGTTAGGGGGTTTCGTTTTTTTTTTCGAT
[0238] GTTTTTTGTTTTTTTTTGGGTTTTCGGAATTTAGTTTGTTTTAATCGTTTTCGTTGCGGG
[0239] TAGCGTTGGTTACGCGGTTTTCGTCGTCGGCGGTTTTTCGTGGTTAAGTATTTTTGGTT
[0240] TTGGAGTTTAGGGGTTGCGTTTTTTTTGGGGTCGGGGCGGGAGAGAGGATTTCGGTG
[0241] GTATTCGTTCGTGCGTTGGGCGSeq ID NO.6
[0242] Methylation site 6:
[0243] GTTGCGCGTTGATCGCGGGGTTCGATATGATGGTTGGTGGGTAGCGGGTCGCGCGGA
[0244] GGGTAGCGGCGAGGAAGCGTTTTCGGCGGGGTTCGGGTTTTGCGCGTTGGTTGGGGC
[0245] GTCGCGTTCGCGTTTTTGTAGTGTAGAGTTAGTCGTCGGAGGAGTTTTTAGGTTTTTT
[0246] GGTTTAGTTGAATGAATGGGGGAGGAAGGCGGGCGTCGGTTTTTTTTCGCGCGSeq ID NO.7
[0247] Methylation site 7:
[0248] TGATTGCGGTTTTTTGGGGGATTTTGCGTTTAGTTCGAAAGTTGGTTTTGTTAAAAGA
[0249] CGTACGGGTAGGAAGGGCGAAAAGGAAATTTTGTATTTCGTCGCGTTGGGTTTTTCG
[0250] AGTTCGTGCGTAAAGCGGTTTACGAGTTTTGGTTTCGTATTTGTAGAGGATAAGAGTT
[0251] AATGTTTAAAAAAGAATAGCGGAGGAATCGGTTGGCGCGGTTAGTTGGAACGTTGGA
[0252] TCGTAGTGCGTTTAGGGAAGGTCGGGGGCGTTCGTCGGTTTTAGTTTTTAGTGGTTTT
[0253] TTTTTACGTCGGTTCGCGCGTGTTTTTGTTTATAAGATTTGGGGCGTTTTGGTTAGATT
[0254] TGGATGGTAGGTTTTTTCGTTATTTTCGGTTCGGTTTCGGGGGCGTGGTTTGGCGCGG
[0255] GGGCGGGTTTAAGTTATCGCGGGTGTTTGATTATTTTGATAGGTTTTTAAATTTTTTTTA
[0256] GTCGTTTGGCGTTCGCGGTGCGTTTTAGAGTTTTAGGGTGGTACGCGGCGGCGTTTTT
[0257] TTAGATTTAGAGGCGTTTTTGTCGATTTTTACGCGGTTTCGGGTTTTTTTTTTTTTTTAA
[0258] ATTTTCGTTTTATTCGTTAAGTTTCGGTTTTTAGTTTTAGATATTCGTATCGGCGGTTTTT
[0259] TTTCGTTTTCGGAGTTTTTGGTTTTGGAGTTTTTATTATTTTTTTTTTTTTTCGTTTTTTT
[0260] TGATTTTTTTAGTTTCGAGTTAAATGGATTTTAAAGAACGAAATAAAGGGSeq ID NO.8
[0261] Methylation site 8:
[0262] TTTTAGATTAGGGTGTTTAGGGGTGGTTATTTGGAGGAGGTGATATTTGAGACGTTAA
[0263] CGAGAACGAGTTAGTTTAGTTTAGAGGAGGTTTAGGGGAAACGCGGTTTAGGTTTGA
[0264] GATTATAAAGGGTATATTAGTGGTTACGAAGTTTTTTGGGGGGAAAATTCGGTAGGTC
[0265] GTCGTCGTCGTTTCGTTAGTAGTTATCGATTTTCGTTTTGAGAGTTCGGAGTTGACGC
[0266] GAAGGAGGGGGTTCGTTTTGGCGCGTTTTTTTTTTCGCGTTATGTATTAGTTAGATGGG
[0267] GAGTCGGGGTGGTTAGGTTTTGGGTCGGGTAAGTTGGATTGTTCGGTCGATTTGTTTT
[0268] TATTTTTCGTTTTTTTTTTTTCGGGGCGGTCGAAGAGTATCGGGTTGATTTTTTTTTTAA
[0269] GTGAAATTGSeq ID NO.9
[0270] Methylation site 9:
[0271] GCGCGGTAGCGTGTTACGGACGGGGACGAGGGGATGGCGGGGACGACGACGTGGGC
[0272] GGTGGGAGTAGAGTGTTTGCGATTTTCGGGGTAGGAAGGAGGGGCGGGATGGTTTTT
[0273] CGCGTTCGAAATTTACGGCGTGGCGGACGCGGAGGAGTTTCGAGTTTTATAATTAAGG
[0274] GGTGGGAAGGAAAAGGGATAGAGCGAGATAGAGCGTTTTCGAGAAASeq ID NO.10
[0275] Methylation site 10:
[0276] ATATTTGGTTTTAAGGTTATTATTTGATATAAAAATATAATGTTGGTTTTTTAAATAGGTA
[0277] ATTTATATTGATATTTATATAGTTTTTATTTATATTTGCGATTATAAGGTAGTATTTTCGGG
[0278] TTTTCGTCGGTTACGATTCGTTTTTAGAGAGTATTCGCGTATAATTTTATTTTATTTACGA
[0279] TTTTGATTTTTTTTTTTTTATTTTTTTAATTTTATTCGGGACGAGATTATTAGGTTTTATTT
[0280] TTATTTTTATTTTTATSeq ID NO.11
[0281] Methylation site 11:
[0282] GGGGAAAGGGTCGGGTAAGGTTCGGATGGAGTAGTTTCGGGAAGGTGCGGGTTTCG
[0283] GCGATCGTTGGATGGTTGTCGTTTTTTCGACGAGTGCGTTTTTCGTAAATGTTTTTTGG
[0284] GGTAAGGGTTTTCGGTTATTGAGTTATGTATAGTAAGTTTAGATCGTAAAAAGATTCGC
[0285] GAAGGGTAGAATATGTCGGTTTTTTCGGTTCGTCGTCGTTTTTAGTTTAGGATGTTTTC
[0286] GAATTTTGGAGTCGAATAGGTTGGGTTTTTTTAGCGCGTTTTATCGCGGTTTAGTTTTA
[0287] TTATTTCGCGCGTTGTTCGTTTTTTCGCGTTTTTGGATTCGT Seq ID NO.12
[0288] Methylation site 12:
[0289] TTATTATCGCGGAATTTTGAAAGCGTAGATTTGTTTTGAAGTTTTGAGCGATTTTTCGT
[0290] ATTAGGCGTTGGAAAGGTAATTTGCGGATTAGTAGTTTAGTCGATTTTTGATAGCGGCG
[0291] AATTTCGCGTAGAGTTACGGTGTCGGGACGGTAGCGATGAGGTTTTTTTACGTCGTCG
[0292] GTGGTCGGCGCGTTTTTTCGAGTCGTTTTAGTGGTTAGTTGTTTGCGCGGCGTTTTGTT
[0293] ATCGGTG
[0294] Seq ID NO.13
[0295] COL2A1:
[0296] TTTTTTGTAAGGAGGGATGTGGAGGGATAGAGGAGTAGTAGGTAAGGTTAGTAGGAG
[0297] GTGATATAGGTAGGGAGGATTAGGTTAAGGTTGGGAGGAGTTTATATTTGGTGTT Seq ID NO.14
[0298] Forward primer of COL2A1:
[0299] ATGTGGAGGGATAGAGGAGTA Seq ID NO.15
[0300] Probe of COL2A1:
[0301] CACCTCCTACTAACCTTACC Seq ID NO.16
[0302] Reverse primer of COL2A1:
[0303] CCTCCCAACCTTAACCTAAT Seq ID NO.17
[0304] Forward primer for methylation site 1:
[0305] GTTGTTTTCGATTTTGTTTTACG Seq ID NO.18
[0306] Probe for methylation site 1:
[0307] CGCCGAAAAACTCTAACCGA Seq ID NO.19
[0308] Reverse primer for methylation site 1:
[0309] CGCACTCCGCTAAAACG Seq ID NO.20
[0310] Forward primer for methylation site 2:
[0311] TGATTTTTAGGTTTTGTGAGGAAA Seq ID NO.21
[0312] Probe for methylation site 2:
[0313] CTCGATATAACGCGCTCGA Seq ID NO.22
[0314] Reverse primer for methylation site 2: AATCTTTACCTTATAATAAAATAAACG Seq ID NO.23
[0315] Forward primer for methylation site 3: GTTTCGTTCGGTATTTTTCGAA Seq ID NO.24
[0316] Probe for methylation site 3: TAACGCCGACCGCGATCT Seq ID NO.25
[0317] Reverse primer for methylation site 3: CGAATAAACCGAACGATAACG Seq ID NO.26
[0318] Forward primer for methylation site 4: GGATTAGGCGGTTTAGTTATTTTTC Seq ID NO.27
[0319] Probe for methylation site 4: CGTTTTCGGTCGCGGC Seq ID NO.28
[0320] Reverse primer for methylation site 4: AACGAACACTAACGAACTTCAATACA Seq ID NO.29
[0321] Forward primer for methylation site 5: CGTTGCGGGTAGCGTTG Seq ID NO.30
[0322] Probe for methylation site 5: TTTTCGTCGTCGGCGGT Seq ID NO.31
[0323] Reverse primer for methylation site 5: AACTCCAAAACCAAAAATACTTAACC Seq ID NO.32
[0324] Forward primer for methylation site 6: GGGGTTCGGGTTTTGC Seq ID NO.33
[0325] Probe for methylation site 6: CGTCGCGTTCGCGTTT Seq ID NO.34
[0326] Reverse primer for methylation site 6: CCGACGACTAACTCTACACTACAA Seq ID NO.35
[0327] Forward primer for methylation site 7: GTTCGTCGGTTTTAGTTTTTAGTG Seq ID NO.36
[0328] Probe for methylation site 7: CGCGCGAACCGACGTA Seq ID NO.37
[0329] Reverse primer for methylation site 7: CGCCCCAAATCTTATAAACAAAA Seq ID NO.38
[0330] Forward primer for methylation site 8: GGGGGGAAAATTCGGTAGG Seq ID NO.39
[0331] Probe for methylation site 8: CTAACGACGACGACGACG Seq ID NO.40
[0332] Reverse primer for methylation site 8: ACTCTCAAAACGAAAATCGATAACT Seq ID NO.41
[0333] Forward primer for methylation site 9: ATGGTTTTTCGCGTTCGAA Seq ID NO.42
[0334] Probe for methylation site 9: TTTACGGCGTGGCGGAC Seq ID NO.43
[0335] Reverse primer for methylation site 9: CCCCTTAATTATAAAACTCGAAACTC Seq ID NO.44
[0336] Forward primer for methylation site 10: TATATTTGCGATTATAAGGTAGTATTTTC Seq ID NO.45
[0337] Probe for methylation site 10: TTTCGTCGGTTACGATTCGT Seq ID NO.46
[0338] Reverse primer for methylation site 10: TAAAATTATACGCGAATACTCTCTAAA Seq ID NO.47
[0339] Forward primer for methylation site 11: ATTCGCGAAGGGTAGAATATGTC Seq ID NO.48
[0340] Probe for methylation site 11: TTCGGTTCGTCGTCGTTT Seq ID NO.49
[0341] Reverse primer for methylation site 11: CAAAATTCGAAAACATCCTAAACTA Seq ID NO.50
[0342] Forward primer for methylation site 12: GCGGATTAGTAGTTTAGTCGATT Seq ID NO.51
[0343] Probe for methylation site 12: TACGCGAAATTCGCCGC Seq ID NO.52
[0344] Reverse primer for methylation site 12: CGTCCCGACACCGTAA.
Claims
1. A use of a marker for preparing a pancreatic cancer detection reagent, characterized in that: The marker is a nucleotide sequence selected from any one or more of Seq ID NO.1 to Seq ID NO.12 or a combination of their completely complementary sequences.
2. The use according to claim 1, characterized in that The marker comprises any one or more nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2, Seq ID NO.3, Seq ID NO.9, Seq ID NO11, and Seq ID NO.
12.
3. The use according to claim 2, characterized in that The marker is a combination of any two, three or six nucleotide sequences of Seq ID NO.1, Seq ID NO.2, Seq ID NO.3, Seq ID NO.9, Seq ID NO11, Seq ID NO.12 or their completely complementary sequences.
4. The use according to claim 3, characterized in that The marker comprises a combination of the nucleotide sequences shown in Seq ID NO.1 and Seq ID NO.2 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.2 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.11 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.2, Seq ID NO.11 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.3, Seq ID NO.9 and Seq ID NO.11 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.3, Seq ID NO.9 and Seq ID NO.12 or their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO. NO.9, Seq ID NO.11 and Seq ID NO.12 or a combination of their completely complementary sequences, or a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2, Seq ID NO.3, Seq ID NO.9, Seq ID NO.11, Seq ID NO.12 or a combination of their completely complementary sequences.
5. The use according to claim 4, characterized in that The marker is a combination of the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2 and Seq ID NO.12 or their completely complementary sequences.
6. The use according to any one of claims 1 to 5, characterized in that The markers also include protein markers, and the protein markers are composed of CA19-9.
7. A primer combination for detecting pancreatic cancer, characterized in that: The primer combination is any one or more of the 12 primer and probe combinations shown in the following table:
8. A kit for detecting pancreatic cancer, characterized in that: Comprising the primer and probe combination as described in claim 7.
9. A marker combination for detecting pancreatic cancer, characterized in that: It comprises methylation sites and protein markers, wherein the methylation sites are selected from any one or more of Seq ID NO.1 to Seq ID NO.12 in the sequence list.
10. The marker combination according to claim 9, characterized in that The methylation sites include the nucleotide sequences shown in Seq ID NO.1, Seq ID NO.2 and Seq ID NO.12 or a combination of their completely complementary sequences.
